Keyphrases
Tumor
100%
Immune Checkpoint Blockade
68%
HPV16
48%
Neoantigen
45%
Oropharyngeal Squamous Cell Carcinoma (OPSCC)
38%
Cancer Types
32%
Immunogenicity
31%
Cancer Immunotherapy
31%
Anticancer Immune Response
29%
Human Leukocyte Antigen Class I
26%
Tumor Immunity
23%
Immune Response
23%
Immunogenic
23%
Tumor mutational Burden
22%
Clinical Genomics
22%
Nivolumab
22%
Tumor Antigen
22%
Microenvironment
22%
Immune Checkpoint Therapy
21%
Programmed Death-ligand 1 (PD-L1)
20%
Immune Microenvironment
19%
Immunotherapy Response
19%
Subclone
19%
Genotype
19%
HLA Class I
19%
Renal Cell Carcinoma
19%
Artificial Intelligence
19%
Serum Antibody
19%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
19%
Clear Cell Renal Cell Carcinoma (ccRCC)
19%
Checkpoint Inhibitor Immunotherapy
19%
Clinical Benefit
16%
T Cells
16%
Checkpoint Inhibitors
16%
Checkpoint Blockade
16%
Overall Survival
16%
In Cancer
16%
MHC Class II
14%
Clinical Data
14%
HLA-I
14%
Cancer Evolution
14%
Response to Immunotherapy
14%
Genomic Features
14%
Clinical Features
14%
Human Leukocyte Antigen
14%
Immune Checkpoint Inhibitors
14%
Early Antigen
14%
Immunogenetics
13%
Evolutionary Divergence
13%
Early Detection
13%
Immunology and Microbiology
Immunotherapy
81%
Immunity
61%
Neoantigen
49%
Human Leukocyte Antigen
43%
T Cell
43%
Immune Checkpoint Blockade
41%
Human Papillomavirus Type 16
38%
Immunology
33%
T Cell Receptor
33%
Immunogenicity
20%
Nivolumab
20%
Squamous Cell
19%
Epitope
19%
Cytotoxic T-Cell
19%
Neck
18%
Early Antigen
14%
Tumor Immunity
14%
Antigenicity
14%
Mutational Load
13%
Heterozygosity
12%
Evolution
12%
Carcinoma Cell
11%
Immune Response
11%
Immunogenetics
11%
Hydrophobicity
11%
Immune Escape
10%
Salivary Gland
9%
Seropositivity
9%
Myeloid
9%
P53
9%
Single-Cell Sequencing
9%
Ebola Virus
9%
Immune Landscape
9%
Cancer Immunotherapy
9%
Gene Fusion
9%
RNA Splicing
9%
Antibody Blood Level
9%
Cancer Cell
8%
Immune Cell Infiltration
8%
Allele
8%
Autoantibodies
7%
Programmed Death 1 Ligand 1
7%
Immunosurveillance
6%
Wart Virus
6%
Germ Cell
5%
Medicine and Dentistry
Immunotherapy
87%
Malignant Neoplasm
67%
Neoplasm
55%
Immune Checkpoint Blockade
46%
Biological Marker
33%
Clear Cell Renal Cell Carcinoma
29%
Human Papillomavirus Type 16
29%
Cancer Types
28%
Oropharynx Carcinoma
28%
Immunity
21%
Immune Response
19%
Head and Neck Squamous Cell Carcinoma
19%
Human Leukocyte Antigen
19%
Kidney Cancer
11%
Logistic Regression Analysis
11%
Cytotoxic T-Cell
11%
Immune Checkpoint Inhibitor
11%
Recurrent Disease
10%
Overall Survival
10%
Early Antigen
10%
Programmed Death 1 Ligand 1
10%
4 Iodo 2,5 Dimethoxyamphetamine
9%
Disease Exacerbation
9%
Autoantibodies
9%
Pembrolizumab
9%
Oropharynx
9%
Medulloblastoma
9%
Ovarian Cancer
9%
Proteus Syndrome
9%
Bladder Cancer
9%
Squamous Cell Carcinoma
9%
Genetic Variability
9%
Medicine
9%
Diagnostic Accuracy
9%
Gene Fusion
9%
T-Cell Response
9%
Lenvatinib
9%
Genome Analysis
9%
Disease Course
9%
Progression Free Survival
9%
Tumor Antigen
7%
Clinical Decision Making
6%
Somatic Mutation
6%
Diseases
6%
Volunteer
5%
HPV-positive Oropharyngeal Cancer
5%
T Cell
5%
Germ Cell
5%